TRCT
AURA icon

Tower Research Capital (TRC)’s Aura Biosciences AURA Stock Holding History

Tower Research Capital (TRC)’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4K Buy
6,952
+3,039
+78% +$21.7K ﹤0.01% 2747
2026
Q1 		$26.2K Buy
3,913
+1,958
+100% +$11.2K ﹤0.01% 3288
2025
Q4 		$10.7K Sell
1,955
-261
-12% -$1.55K ﹤0.01% 3726
2025
Q3 		$13.7K Sell
2,216
-4,156
-65% -$27.2K ﹤0.01% 3662
2025
Q2 		$39.9K Buy
6,372
+2,104
+49% +$12.3K ﹤0.01% 3165
2025
Q1 		$25K Buy
4,268
+1,166
+38% +$8.82K ﹤0.01% 2767
2024
Q4 		$25.5K Buy
3,102
+403
+15% +$3.79K ﹤0.01% 3006
2024
Q3 		$24K Sell
2,699
-1,983
-42% -$17K ﹤0.01% 3137
2024
Q2 		$35.4K Buy
4,682
+1,528
+48% +$11.2K ﹤0.01% 3361
2024
Q1 		$24.8K Sell
3,154
-1,143
-27% -$9.48K ﹤0.01% 2806
2023
Q4 		$38.1K Sell
4,297
-2,307
-35% -$19.5K ﹤0.01% 3302
2023
Q3 		$59.2K Buy
6,604
+4,758
+258% +$51.2K ﹤0.01% 2404
2023
Q2 		$22.8K Buy
1,846
+770
+72% +$8.23K ﹤0.01% 3270
2023
Q1 		$10K Sell
1,076
-2,459
-70% -$25.5K ﹤0.01% 4326
2022
Q4 		$37K Buy
3,535
+2,273
+180% +$28.9K ﹤0.01% 2553
2022
Q3 		$23K Sell
1,262
-2,687
-68% -$40.7K ﹤0.01% 3804
2022
Q2 		$56K Buy
3,949
+2,840
+256% +$47K ﹤0.01% 2774
2022
Q1 		$24K Buy
1,109
+451
+69% +$8.59K ﹤0.01% 3353
2021
Q4 		$11K Buy
+658
New +$11.8K ﹤0.01% 4383

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Tower Research Capital (TRC)'s AURA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Aura Biosciences (AURA) stake by 78% in Q2 2026, buying an estimated $21.7K and bringing the position to 6,952 shares worth $49.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2747.

Tower Research Capital (TRC) first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. The position peaked at $59.2K in Q3 2023. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Tower Research Capital (TRC) held 6,952 shares of Aura Biosciences worth $49.4K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,039 Aura Biosciences shares in Q2 2026, an estimated $21.7K.
  • Aura Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2747 holding.
  • Tower Research Capital (TRC) first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Aura Biosciences position peaked at $59.2K in Q3 2023.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.